https://www.selleckchem.com/pr....oducts/cdk2-inhibito
Carisoprodol (Soma®) is a centrally-acting skeletal-muscle relaxant frequently prescribed for treatment of acute musculoskeletal conditions. Carisoprodol's mechanism of action is unclear and is often ascribed to that of its active metabolite, meprobamate. The purpose of this study was to ascertain whether carisoprodol directly produces behavioral effects, or whether metabolism to meprobamate via cytochrome P450 (CYP45 enzymatic reaction is necessary. Rats were trained to discriminate carisoprodol (100 mg/kg) to assess time c